NasdaqGS:BIIBBiotechs
Biogen (BIIB) Expands Its Alzheimer’s Pipeline, Is The 9% Undervaluation Still There?
Biogen (BIIB) is back in focus after a cluster of Alzheimer’s related updates, including FDA approval for at home LEQEMBI IQLIK injections and new Phase 2 data for its tau targeting candidate diranersen.
See our latest analysis for Biogen.
Biogen’s share price has been under near term pressure, with a 1 day share price return of 2.93% and 7 day share price return of 4.34%, even as Alzheimer’s updates keep attention on the stock. At the same time, a 90 day share price return of 7.53% and 1...